Beractant
- Atc Codes:R07AA02
- CAS Codes:108778-82-1
- PHARMGKB ID:108778-82-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Survanta; Belgium: Survanta; Bulgaria: Survanta; Cyprus: Survanta; Czech Republic: Survanta; France: Survanta; Germany: Survanta; Greece: Survanta; Hungary: Survanta; Ireland: Survanta; Luxembourg: Survanta; Netherlands: Survanta; Poland: Survanta; Slovenia: Survanta; Spain: Survanta; Sweden: Survanta-Vent; UK: Survanta.
North America
Canada: Survanta; USA: Survanta.
Latin America
Brazil: Alveofact, Survanta; Mexico: Survanta.
Drug combinations
Chemistry
Beractant: A modified bovine lung extract containing mostly phospholipids, modified by the addition of dipalmitoylphosphatidylcholine (DPPC), palmitic acid, and tripalmitin. CAS-108778-82-1. (1989).
Pharmacologic Category
Pulmonary Surfactants. (ATC-Code: R07AA02).
Mechanism of action
Natural bovine lung extract which replaces deficient or ineffective endogenous lung surfactant in neonates with/at risk of respiratory distress syndrome.
Therapeutic use
Prevention or rescue treatment of hyaline membrane disease (respiratory distress syndrome) in premature neonates. Can reduce the incidence of respiratory distress syndrome, mortality secondary to respiratory distress syndrome, and air leak complications (e.g. pneumothorax, pneumopericardium).
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Warnings and precautions
Rapidly affects oxygenation and lung compliance. Transient episodes of bradycardia and decreased oxygen saturation occur.